Showing 7031-7040 of 9462 results for "".
- Comparative Study Finds No Significant Melanoma Mortality Reduction From German Screening Initiativehttps://practicaldermatology.com/news/comparative-study-finds-no-significant-melanoma-mortality-reduction-from-german-screening-initiative/2487471/A study of a German nationwide skin cancer screening (SCS) program showed reduced melanoma mortality compared with neighboring European countries that do not have population-based screening programs. Germany launched its nationwide SCS program in 2008, which included adults aged 35 years a
- Study Links Childhood Adversity to Mitochondrial Changes and Atopic Dermatitis Riskhttps://practicaldermatology.com/news/study-links-childhood-adversity-to-mitochondrial-changes-and-atopic-dermatitis-risk/2487465/A new study published in Psychoneuroendocrinology suggests that adverse childhood experiences (ACEs) may contribute to biologic changes associated with atopic disease, identifying mitochondrial DNA copy number (mtDNAcn) as a
- Oral Nicotinamide Linked to Fewer Skin Cancers and Lower Treatment Costshttps://practicaldermatology.com/news/oral-nicotinamide-linked-to-fewer-skin-cancers-and-lower-treatment-costs/2487444/Oral nicotinamide may offer a cost-effective strategy for preventing keratinocyte carcinoma (KC) in patients at high risk for developing multiple skin cancers, according to a new economic evaluation conducted within the Veterans Health Administration (VHA) published in JAMA Dermatology.<
- SCRATCH-AD: Rapid Itch Reduction, Biomarker Improvements with Ruxolitinibhttps://practicaldermatology.com/news/scratch-ad-rapid-itch-reduction-biomarker-improvements-with-ruxolitinib/2487381/Patients with atopic dermatitis (AD) treated with ruxolitinib 1.5% cream experienced rapid and sustained reductions in itch alongside improvements in disease-associated biomarkers, according to findings from the SCRATCH-AD study. The open-label SCRATCH-AD trial (NCT04839380) evaluated the
- Avapritinib Shows Dermatologic Benefits in Indolent Systemic Mastocytosishttps://practicaldermatology.com/news/avapritinib-shows-dermatologic-benefits-in-indolent-systemic-mastocytosis/2487380/Treatment with avapritinib led to substantial improvements in cutaneous disease manifestations among patients with indolent systemic mastocytosis (ISM), according to results from the phase 2 PIONEER study. Investigators for
- Analysis: Capecitabine Shows Clinical Activity in Advanced Head and Neck Cutaneous SCChttps://practicaldermatology.com/news/neoadjuvant-capecitabine-yields-42-complete-pathologic-response-rate-in-advanced-cscchn/2487303/Neoadjuvant capecitabine demonstrated encouraging clinical and pathologic responses in patients with advanced cutaneous squamous cell carcinoma of the head and neck (cSCCHN), according to findings from a prosp
- Familial Melanoma Genes Associated With Expanded Spectrum of Malignancieshttps://practicaldermatology.com/news/familial-melanoma-genes-associated-with-expanded-spectrum-of-malignancies/2487300/A new study published in JAMA Dermatology suggests pathogenic variants (PVs) in familial melanoma susceptibility genes are present in up to 0.9% of the general population. Investigators for the
- Rubedo Reports Early Clinical Activity for GPX4 Modulator RLS-1496 in Actinic Keratosishttps://practicaldermatology.com/news/rubedo-reports-early-clinical-activity-for-gpx4-modulator-rls-1496-in-actinic-keratosis/2487263/Rubedo Life Sciences announced preliminary findings from a Phase 1b/2a trial evaluating topical RLS-1496 1% cream in adults with actinic keratosis (AK), reporting reductions in lesion counts alongside favorable tolerability data. The interim findings were presented at the RBC Capital Markets Glob
- Swiftscope App Integrates Dermatoscopy With SwiftPro Wart Treatmentshttps://practicaldermatology.com/news/swiftscope-app-integrates-dermatoscopy-with-swiftpro-wart-treatments/2487231/Emblation has launched the Swiftscope app, a new digital imaging platform designed to help clinicians visually monitor treatment progress in patients undergoing SwiftPro microwave therapy for common and plantar warts, according to a news release. The announcement f
- FDA Approves OTC Switch for Galderma’s Differin Epiduo Acne Gelhttps://practicaldermatology.com/news/fda-approves-otc-switch-for-galdermas-differin-epiduo-acne-gel/2487203/The US Food and Drug Administration (FDA) has approved Galderma’s Differin Epiduo Acne Gel (adapalene 0.1% and benzoyl peroxide 2.5%) for over-the-counter (OTC) use in patients aged 12 years and older, marking a notable prescription-to-OTC transition in acne therap